High quality rapid tests for medical professional use
As a German manufacturer of safe and easy-to-use products in the field of point-of-care diagnostics, MEXACARE GmbH has expanded its portfolio to include two reliable, safe and easy-to-use Covid-19 rapid tests due to the high demand and urgency.
OUR COVID-19 RAPID TESTS ARE THE URGENT ANSWER TO A CHALLENGE THAT LEAVES NO TIME FOR ANY OF US
Like all our rapid tests, the Covid-19 rapid tests are designed for daily practice routine and are characterized by great user-friendliness and highest reliability. Manufactured according to the latest manufacturing standards, all rapid tests can be performed and evaluated without the need for laboratory equipment.
THE CONTROL OF THE SARS-COV-2 VIRUS PLACES EXTREME DEMANDS ON ALL INVOLVED
On this page you will find all information about the MEXACARE Covid-19 rapid tests, a Covid-19 guide, brochures and the operating instructions for our tests as downloads.
Covid-19 rapid tests
On this page you will find all information about the MEXACARE Covid-19 rapid tests, a Covid-19 guide, brochures and the operating instructions for download.
COVID-19 Antigen Rapid Test
What is the MEXACARE COVID-19 Antigen Rapid Test?
The MEXACARE Coronavirus Antigen Rapid Test is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 antigens present in the human nasopharynx. One antigen (protein of COVID-19) is usually detectable in upper respiratory tract samples during the acute phase of infection. Positive results indicate the presence of viral antigens.
95.65% (95 % CI*: 91.9 %-99.4%)
99.38% (95 % CI*: 98.5%->99.9%)
98.39% (95 % CI*: 97.2%-99.57%)
When should I test with the MEXACARE COVID-19 Antigen Rapid Test
Like the RT-PCR test. which is currently the gold standard. an antigen test is able to detect infection with the novel coronavirus SARS-CoV 2 very early after infection.
In the earliest stages of the disease – during the incubation period (according to the WHO an average of 5-6 days) and in the first 2-3 days after the onset of symptoms. a test with the MEXACARE COVID-19 Antigen Rapid Test is therefore recommended. Since the test detects protein components of the actual virus (so-called antigens) and not antibodies (the immune reaction of the human body against the virus). acute infections with SARS-CoV-2 can be detected at this early stage.
The benefits of the MEXACARE COVID-19 Antigen Rapid Test
• Very high sensitivity (>93 %) and specificity (>98 %)
• Fast availability of test results (approx. 15 minutes)
• No expensive laboratory equipment needed
• No additional reagents required
• All materials for direct on-site testing included (Point-of-Care)
• No need to transport samples to the laboratory
Influenza A+B Rapid Test
Infectious disease marker
The MEXACARE Influenza A+B Antigen Rapid Test is a rapid chromatographic immunoassay for the selective and qualitative detection of Influenza A and Influenza B virus antigens in human nasopharynx.
> 99.9 %
Due to the similarity of the symptoms to influenza, it is reasonable to additionally perform an Influenza A+B rapid test in case of a COVID-19 suspicion. Thus one can exclude on the one hand that not perhaps a double infection is present (COVID-19 and flu), on the other hand in addition, a viral flu can be excluded with cold symptoms. With its high sensitivity and specificity, the MEXACARE Influenza A+B Rapid Test is a reliable tool for the diagnosis of respiratory tract infections.
COVID-19 & Influenza A+B Ag Combo
Infectious disease marker
The MEXACARE COVID-19 & Influenza A+B Ag Combo Rapid Test is a rapid chromatographic immunoassay for the selective and qualitative detection of SARS-CoV-2, Influenza A and Influenza B virus antigens in the human nasopharynx.
The MEXACARE COVID-19 & Influenza A+B Antigen Combo Rapid Test greatly facilitates the diagnosis of conspicuous respiratory symptoms. A single smear is sufficient to test patients for both COVID-19 and influenza A+B. Due to the similarity of symptoms of both infections (cough, rhinitis, neck scratching, fever) it is recommended to perform the test for both infections.
The COVID-19 IgG/IgM Rapid Test is a rapid, qualitative immunochromatographic in vitro test for the differential detection of IgM & IgG antibodies against the SARS CoV-2 virus in human serum, plasma or whole blood samples. The test is intended for the determination of a current or past infection with the SARS-CoV-2 virus and for monitoring the disease status after SARS-CoV-2 virus infection. To evaluate the performance of the MEXACARE COVID-19 IgG/IgM Rapid Test, a total of 1,615 patient samples were tested in several clinical studies in the USA, Canada, China and Germany.
The MEXACARE COVID-19 IgG/IgM Rapid Test shows a sensitivity of 99.03 % and a specificity of 99.53 % only 7 days after the onset of symptoms.
MEXACARE COVID-19 IgG/IgM Rapid Test
The accuracy of the test is thus 99.28 %.
When should I test with the COVID-19 IgG/IgM Rapid Test?
The COVID-19 IgG/IgM Rapid Test is intended to complement the RT-PCR tests, which are currently performed in large numbers by doctors, laboratories and public health authorities throughout the world in the fight against the novel Corona-Virus SARS-CoV-2.
During the earliest stages of the disease – in the incubation period (according to WHO around 5-6 days on average) and on the first 2-3 days after the onset of symptoms – only RT-PCR can give you satisfactory test results as the body has not produced antibodies in detectable quantities.
5-7 days after the onset of the disease symptoms (cough, slight fever, sore throat) IgM antibodies can already be detected in the blood. After this period of approx. 7 days, we recommend testing with the COVID-19 IgG/IgM rapid test, as positive results can now be obtained with a high degree of certainty. IgG antibodies are later produced by the immune system and can be detected in the body long after recovery. In this way, undetected infections (e.g. infections without symptoms) or the serological protection of the test subject can be determined.
Why are antibody tests useful?
Antibody tests can fill a diagnostic gap. In the earlier phases of the disease – several days after the onset of symptoms – the IgM antibody test can be used to screen for active infections with SARS-CoV-2 and help to distinguish between COVID-19 and other respiratory diseases such as influenza or RSV. In the later stages, the IgG antibody test can help to detect previously undetected infections and screen the serological immunity of large numbers of the population. In addition, the IgG antibodies remain in the body for a long time after the patient has recovered. Therefore, the result is a marker for successful convalescence in ONLY IgG-positive patients.
Since antibody tests are much faster and easier to perform, the extended use of these tests could relieve the laboratories and help to keep capacity at the same level.
The benefits of the MEXACARE COVID-19 IgG/IgM Rapid Test:
• Test device for qualitative and selective detection
• Fast, easy, inexpensive – No lab equipment needed
• Safe point of care test with result within 15-20 minutes
• High sensitivity (>99%) as early as 7 days after the onset of symptoms
• High specificity (>99%) enables rapid detection of infected persons
• Detection of antibodies even in patients without symptoms
• Complements MEXACARE Corona Antigen Rapid Test and RT-PCR as a powerful tool for comprehensive assessment of virus distribution
• Approved reliability through extensive clinical studies (more than 1600 subjects from 4 countries)
• Important diagnostic gap for the detection of an earlier immune reaction is closed
• Proof of immunity of patients, and to lift quarantine measures
• Offers the possibility of effective screening of large parts of the population
• Compared to competitive products, the COVID-19 IgG/IgM Antibody Test has clearer bands, which makes it easier to read